Compare Flagstar Bank NA (FLG) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Flagstar Bank NA trades at $11.07 (market cap $4.61B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Flagstar Bank NA is far larger — about 4.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Flagstar Bank NA pays a 0.36% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 23 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FLG | MRVI | |
|---|---|---|
Market Cap | $4.61B | $977.37M |
Volume | 4,112,400 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $15.36 | $9.00 |
52-Week Low | $10.72 | $2.83 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $15.13B | $1.08B |
Dividend Yield | 0.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.88% with a bearish technical outlook despite recent earnings beats in Q4 2025 and Q1 2026. The stock shows mixed fundamentals with a low P/B ratio of 0.61x but elevated P/E of 373.67x, while profitability metrics remain weak with net income margin at 2.3%. Recent news highlights strategic partnerships and a $250 million share repurchase program, though Q2 2026 earnings missed expectations.
Wall Street maintains a bullish consensus with 60% buy ratings and a $16.81 price target, representing 50% upside potential. Key risks include volatile earnings performance, high valuation multiples, and negative cash flow trends. The company's turnaround efforts and strong capital position provide potential catalysts, but execution risks remain significant.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
